Overview

Spectroscopic MRI-Guided Radiation Therapy Planning in Glioblastoma

Status:
Active, not recruiting
Trial end date:
2022-01-01
Target enrollment:
Participant gender:
Summary
This pilot clinical trial studies the side effects of spectroscopic magnetic resonance imaging (MRI)-guided radiation therapy and how well it works in treating patients with newly-diagnosed glioblastoma or gliosarcoma. Spectroscopic MRI can show doctors where the extent of tumor is in the brain beyond current clinical MRI scans by mapping areas of high tumor metabolism. Radiation therapy uses high energy beams to kill tumor cells and shrink tumors. Spectroscopic MRI-guided radiation therapy may work better in treating patients with glioblastoma or gliosarcoma.
Phase:
Phase 2
Details
Lead Sponsor:
Emory University
Collaborators:
Johns Hopkins University
National Cancer Institute (NCI)
University of Miami
Treatments:
Temozolomide